There are 2789 resources available
626P - Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study
Presenter: Nobuaki Matsubara
Session: ePoster Display
627P - Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates
Presenter: Eugene Shenderov
Session: ePoster Display
743P - Real-world outcomes in patients treated with trametinib for low grade serous ovarian carcinoma
Presenter: Rohan Shotton
Session: ePoster Display
744P - Use of PARPi among patients with advanced ovarian cancer: Results from a real-world database
Presenter: Shaheenah Dawood
Session: ePoster Display
746P - Real-world clinical outcomes of patients with de novo advanced high-grade epithelial ovarian cancer eligible to niraparib maintenance in France
Presenter: Manuel Rodrigues
Session: ePoster Display
747P - Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study
Presenter: Mark Lythgoe
Session: ePoster Display
748P - Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Presenter: Margarita Romeo Marin
Session: ePoster Display
628P - Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
Presenter: Neal Shore
Session: ePoster Display
629P - Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy
Presenter: Brian Gonzalez
Session: ePoster Display